RxDoctor Payments DataLook up a doctor →

Sonia Rente, MD

General Practice · Miami, FLNPI 1063400364

Payments from drug & device makers

$2,469,678in general payments, 2019–2025

Across 460 payments — averaging $5368.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1M
  • E.r. Squibb & Sons, L.L.C.$558K
  • Acadia Pharmaceuticals Inc$325K
  • AbbVie$298K
  • H. Lundbeck A S$207K
  • Biohaven Pharmaceutical Holding Company Ltd.$25K
  • plus $47K from 6 others
$1,059in research payments, 2019–2025

Across 10 payments — averaging $105.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$1K

What the payments were for

  • Food & beverage$1,97799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,469,678 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$9,368
Medicare patients
34
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$32,477
Memantine Hcl ErMemantine Hcl17$3,936
Aripiprazole24$2,404
Doxepin Hcl12$1,228
Alprazolam177$1,227
Vilazodone Hcl13$1,085
Bupropion XlBupropion Hcl38$881
Clonazepam52$728
Temazepam73$720
Gabapentin41$574
Vitamin D2Ergocalciferol (Vitamin D2)34$490
Paroxetine Hcl22$472
Zolpidem Tartrate75$447
Trazodone Hcl19$403
FenofibrateFenofibrate Nanocrystallized12$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$297,929$32,47712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →